不同剂量阿托伐他汀治疗急性ST段抬高型心肌梗死急诊PCI术后疗效比较

目的 对比不同剂量阿托伐他汀治疗组的炎性指标及安全性指标,为国人急性ST段抬高型心肌梗死合理应用调脂药物提供依据.方法 111例急性ST段抬高型心肌梗死并行急诊PCI术的患者按随机量表分为阿托伐他汀40 mg及20 mg治疗组,检测术前及术后1个月炎性因子、超声心动图、血脂等疗效指标及肝肾功能等安全性指标.结果 阿托伐他汀40 mg治疗组在调脂、抗炎及改善左心室功能方面优于20 mg治疗组,且两组间副作用没有明显差异.结论 40 mg阿托伐他汀在国人急性ST段抬高型心肌梗死急诊PCI术后应用是安全有效的.

Curative Effect Comparison of Different Doses of Atrovatatin in Acute ST-Segment Elevation Myocardial Infarction After Emergence Percutaneous Coronary Intervention

AimTo contrast inflammatory level and safety of different doses atorvastatin (lipitor) treatment group, and to find basis for lipid-drugs to use in acute ST-segment elevation myocardial infarction (STEMI) reasonably.Methods111 patients with STEMI were divided into two groups according to different doses of atorvastatin after percutaneons coronary intervention: 40 mg/d treatment group, 20 mg/d treatment group.The therapeutical effect was tested including inflammatory factors,lipid-level and UCG of preoperative and postoperative 1 month, and including hepatic function and renal function of preoperative and postoperative 1 month.ResultsThe lipid-lowering,anti-inflammatory,improving left venticular function of atorvastatin 40 mg treatment group were better than the atorvastatin 20 mg treatment group, but the side effect had no difference between the two groups.ConclusionsIn China, atorvastatin 40 mg/d in STEMI after percutaneons coronary intervention may be safe and effective.